All In Biotech

Drug Trial Radar · NCT04404530

Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)

Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the Metabolome

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Oct 8, 2019

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioMarin Pharmaceutical
First posted
May 27, 2020

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phenylketonuria (PKU) is an inherited metabolic disorder that impairs the metabolism of the essential amino acid phenylalanine (Phe). Without stringent dietary control, Phe accumulates in the blood and brain of PKU patients, leading to severe cognitive deficits. Achieving metabolic control, defined as blood Phe levels within the range of 120-360 μmol/L, has been a significant challenge for PKU patients using traditional diet therapy. The new FDA approved pharmacologic treatment, Palynziq, offers a new approach that could significantly reduce the burden of PKU by improving blood Phe levels and allowing for a less restrictive diet. As little is known about the global metabolic and physiologic effects of Palynziq, the present study aims to capture changes in diet quality, neurological health, nutritional status, the nutritional metabolome, and patient perceptions of mental and social health with sustained Palynziq therapy.

Conditions

  • Phenylketonurias

Interventions

  • PalynziqDrug

    Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intra-subject Change in Intact Protein IntakeTime frame: Baseline through 12 Months Post-Response (up to 14 months after baseline)
  2. Intra-subject Change in Medical Food Protein IntakeTime frame: Baseline through 12 Months Post-Response (up to 14 months after baseline)
  3. Sub study: Intra-subject change in intact protein and medical food protein intake.Time frame: 12 Months Post-Response through additional five years (6 years post-response)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital Georgia Clinical Research Center

    Atlanta, Georgia · Recruiting

  • The Emory Clinic

    Atlanta, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.